Heart rate as a cardiovascular risk factor: Potential clinical benefit with ivabradine;Fréquence cardiaque comme facteur de risque cardiovasculaire: Potentiel de l'ivabradine

Revue Medicale Suisse

Volumn 3, Issue 113, 2007, Pages 1375-1382

  Purcell, Henry ^a   Mach, François ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b Service de Cardiologie   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DILTIAZEM; IVABRADINE; METOPROLOL; OXPRENOLOL; PINDOLOL; PLACEBO; PRACTOLOL; PROPRANOLOL; SOTALOL; TIMOLOL; VERAPAMIL;

CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; PACEMAKER; PATIENT CARE; REVIEW; SINUS NODE; SINUS NODE CONDUCTION VELOCITY; STABLE ANGINA PECTORIS; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

BENZAZEPINES; CARDIOVASCULAR DISEASES; HEART RATE; HUMANS; RISK FACTORS;

EID: 34250903588     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Purcell H. Heart rate as a therapeutic target in ischaemic heart disease. Eur Heart J 1999;1(Suppl.):S58-63.
2. Purcell H. Is heart rate a prognostic factor for cardiovascular disease? Dialogues in Cardiovascular Medicine 2001;6:32-6.
3. ** Cook S, Togni M, Schaub MC, et al. High heart rate: A cardiovascular risk factor? Eur Heart J 2006;27:2387-93.
4. Shaper AG, Wannamethee G, MacFarlane PW, et al. Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men. Heart 1993;70:49-55.
5. Mensink GBM, Hoffmeister H. The relationship between resting heart rate and all-cause, cardiovascular and cancer mortality. Eur Heart J 1997;18:1404-10.
6. * Jouven X, Empana J-P, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005;352:1951-8.
7. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001;104:1477-82.
8. Sajadieh A, Nielsen OW, Rasmussen V, et al. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 2004;25:363-70.
9. Purcell H. The coronary and cardiovascular risks of a high basal heart rate. Prac Cardiovasc Risk Management 2006;4:2-4.
10. Patel SR, Breall JA, Diver DJ, et al. Bradycardia is associated with development of coronary collateral vessels in humans. Cor Art Dis 2000;11:467-72.
11. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute long-term myocardial intervention trials. Am J Cardiol 1986;57:43F-49.
12. f inhibition: New perspectives. Medicographia 2005;27:51-5.
13. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective If current inhibition with ivabradine. Drugs 2004;64:1757-65.
14. Borer JS, Fox K, Jaillon P, et al. Ivabradine Investigators Group. Antianginal and anti-ischemic effects of ivabradine an If inhibitor in stable angina:A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107:817-23.
15. f current Inhibitor ivabradine in patients with chronic stable angina. A one-year randomized double-blind multicentre trial. Eur Heart J 2004;25(Suppl.):876.
16. f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-36.
17. f current inhibitor ivabradine compared to amlodipine as monotherapies in patients with chronic stable angina. A randomized controlled double-blind trial. Eur Heart J. 2004;25(Suppl.):878.
18. Camm AJ, Lau C. Electrophysiological effects of a single intravenous administration of ivabradine in adults with normal baseline electrophysiology. Drugs R D 2003;4:83-9.
19. f current blocker ivabradine on ventricular repolarisation: Analysis based on a population heart rate correction formula. J Am Coll Cardiol 2005 (Abstract) 1023-272.
20. Camm AJ, Le Heuzey J-Y, Jern S. Ivabradine significantly increases heart rate variability compared with amlodipine in patients with chronic stable angina: A 3-month randomized double-blind controlled study. Presentation at World Congress of Cardiology, Barcelona, 2006.
21. f current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004;109:1674-9.